Hybrigenics participates in Masterswitch project
Hybrigenics, a French bio-pharmaceutical company focused on cancer treatments and protein interactions, has signed a Euro 400,000 contract as part of a large-scale European Union research project called Masterswitch (Mechanisms to Attack STeering Effectors of Rheumatoid Syndromes With Innovative Therapy Choices).
Hybrigenics, a French bio-pharmaceutical company focused on cancer treatments and protein interactions, has signed a Euro 400,000 contract as part of a large-scale European Union research project called Masterswitch (Mechanisms to Attack STeering Effectors of Rheumatoid Syndromes With Innovative Therapy Choices).
The firm will deploy its protein interaction expertise in the field of chronic inflammatory diseases and develop a high throughput assay and screen its 100,000 compound library and its collection of about 2,000 natural substances. The aim is to identify small-molecule inhibitors of a therapeutically relevant protein interaction. An optimisation programme will then be conducted in close collaboration with UK-based Dr Frederique Ponchel of Leeds Institute of Molecular Medicine and Cranfield University's Professor Richard Aspinall.
Hybrigenics will receive more than â"šÂ¬400,000 over the first two years of the five-year consortium agreement.
"This EU contract is the recognition at international level of the excellence of Hybrigenics' expertise in this area of protein interaction assay development and screening," said Remi Delansorne, ceo at Hybrigenics.
Masterswitch is part of the EU's 7th Framework Programme and involves a 16-strong consortium coordinated by Professor Tom Huizinga of Leiden University Medical Centre in The Netherlands. Its main objective is to tackle chronic inflammatory diseases using new therapeutic approaches, including a novel protein interaction pathway.